372 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Ironwood Stock Up, Heart Candidate Gets Fast Track Status http://www.zacks.com/stock/news/323183/ironwood-stock-up-heart-candidate-gets-fast-track-status?cid=CS-ZC-FT-323183 Sep 14, 2018 - The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
AbbVie Faces California Insurance Department Suit for Humira http://www.zacks.com/stock/news/323897/abbvie-faces-california-insurance-department-suit-for-humira?cid=CS-ZC-FT-323897 Sep 19, 2018 - AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.
Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap http://www.zacks.com/stock/news/325203/aldeyra-surges-on-positive-dry-eye-study-data-on-reproxalap?cid=CS-ZC-FT-325203 Sep 27, 2018 - Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq http://www.zacks.com/stock/news/328751/eyepoint-eypt-gets-fda-approval-for-eye-therapy-yutiq?cid=CS-ZC-FT-328751 Oct 17, 2018 - EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
What's in Store for Centene (CNC) This Earnings Season? http://www.zacks.com/stock/news/329257/whats-in-store-for-centene-cnc-this-earnings-season?cid=CS-ZC-FT-329257 Oct 18, 2018 - Centene's (CNC) third quarter should exhibit strong performances by its Government-backed and Medicaid businesses.
Universal Health Services (UHS) Q3 Earnings: A Beat in the Cards? http://www.zacks.com/stock/news/330838/universal-health-services-uhs-q3-earnings-a-beat-in-the-cards?cid=CS-ZC-FT-330838 Oct 24, 2018 - United Health's (UHS) third quarter is likely to gain from solid segmental performances and higher number of admissions.
Teva (TEVA) to Report Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/332222/teva-teva-to-report-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-332222 Oct 29, 2018 - While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Is a Beat in Store for Editas (EDIT) This Earnings Season? http://www.zacks.com/stock/news/333611/is-a-beat-in-store-for-editas-edit-this-earnings-season?cid=CS-ZC-FT-333611 Oct 31, 2018 - On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus http://www.zacks.com/stock/news/334564/pharma-stock-roundup-pfe-agn-q3-earnings-lly-nvs-collaboration-deals-in-focus?cid=CS-ZC-FT-334564 Nov 02, 2018 - Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise http://www.zacks.com/stock/news/334690/teva-teva-q3-earnings-beat-2018-eps-view-up-shares-rise?cid=CS-ZC-FT-334690 Nov 02, 2018 - Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.

Pages: 1...29303132333435363738

<<<Page 34>